Welcome to our dedicated page for LakeShore Biopharma Co., Ltd. SEC filings (Ticker: LSBWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LakeShore Biopharma Co., Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LakeShore Biopharma Co., Ltd.'s regulatory disclosures and financial reporting.
LakeShore Biopharma Co., Ltd. has completed a cash merger in which each ordinary share (other than excluded and dissenting shares) was cancelled in exchange for US$0.066 per share. As a result, the reporting investor group now reports 0 shares and 0% beneficial ownership.
The company became a wholly owned subsidiary of the merger parent at the effective time on June 24, 2026. Public trading of the ordinary shares and warrants on OTC Pink is expected to cease, and the company plans to file Form 15 to suspend and ultimately terminate its SEC reporting obligations.
LakeShore Biopharma Co., Ltd has completed a going private merger with Oceanpine Skyline Inc., under which shareholders will receive US$0.066 in cash for each ordinary share. The deal was effected through a merger with Oceanpine Merger Sub Inc., a wholly owned subsidiary of Oceanpine Skyline Inc.
Following the merger, LakeShore Biopharma became a wholly owned subsidiary of Oceanpine Skyline Inc. and will cease to be a publicly traded company. The company plans to file a Form 15 to suspend and eventually terminate its U.S. reporting obligations, and its OTC Pink trading symbols are expected to be removed by FINRA.
Registered holders entitled to the merger consideration will receive instructions from the paying agent on how to surrender their shares in exchange for cash. Any trades in the company’s securities after completion of the merger but before OTC symbol removal will not be valid, as the shares are no longer outstanding.
LakeShore Biopharma reports that shareholders have approved its previously announced merger agreement with Oceanpine Skyline Inc. and its wholly owned subsidiary. At an extraordinary general meeting, about 92.3% of outstanding ordinary shares were represented, and approximately 86.2% of votes cast supported the merger proposals. The merger, agreed in November 2025 and amended in April 2026, remains subject to conditions in the merger agreement. If completed, LakeShore Biopharma will become a wholly owned subsidiary of Oceanpine Skyline and a privately held company, and its shares and warrants will be removed from OTC quotation and will cease to be registered under the U.S. securities laws.
LakeShore Biopharma has called an extraordinary general meeting of shareholders on June 19, 2026 in Beijing to vote on a previously announced going‑private merger with Oceanpine Skyline Inc. and its subsidiary.
If approved and completed, the merger would make the company a wholly owned subsidiary of Oceanpine Skyline Inc., its ordinary shares and warrants would stop trading on public quotation systems, and its securities would cease to be registered under the U.S. Exchange Act. Shareholders of record as of May 27, 2026 are entitled to vote, and the board, following a special committee’s unanimous recommendation, has resolved to recommend a FOR vote on the merger agreements and related transactions.
LakeShore Biopharma’s major shareholders have amended their go‑private deal, sharply cutting the proposed cash payout to public investors. The Amended Merger Agreement reduces the per share merger consideration from US$0.90 to US$0.066, implying about US$1.3 million to buy out outstanding ordinary shares not held by rollover shareholders. The lead reporting person, Huaqin Xue, is deemed to beneficially own 21,021,332 ordinary shares, or 51.0% of the company based on 41,212,693 shares outstanding as of June 30, 2025. Several funds, including Oceanpine, Adjuvant, MSA Growth, Superstring and Epiphron, report smaller holdings below 2% each. Termination fees are also reduced to US$50,000 for the company and US$100,000 for the parent. If the merger closes, LakeShore Biopharma’s ordinary shares would be deregistered and cease trading on the OTC Pink Open Market.
LakeShore Biopharma entered into an amended merger agreement with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. for a going‑private transaction implying an equity value of approximately US$2.7 million. Each ordinary share will be cancelled for US$0.066 in cash, other than excluded and dissenting shares.
The new per‑share cash price, described as amended merger consideration, is reduced from US$0.90 to US$0.066 but represents premiums of about 46.7% to the March 24, 2026 closing price and 23.3% to the 10‑day volume‑weighted average price. Termination fees are cut to US$50,000 for the company and US$100,000 for the parent, and the termination date is extended to nine months from the amendment date.
The board, acting on the unanimous recommendation of a three‑member independent Special Committee, approved the amended deal and recommends shareholder approval. Rollover shareholders holding about 53.35% of voting rights agreed to support the merger. Closing is currently expected in the third quarter of 2026, after customary conditions and a shareholder vote. If completed, LakeShore Biopharma will become privately held and its shares will cease trading on the OTC Pink Open Market.
LakeShore Biopharma Co., Ltd. director and President/CBO Shao Hui David filed an initial ownership report showing holdings of Ordinary Shares. He directly owns 133,360 Ordinary Shares and is also deemed to beneficially own 180,278 Ordinary Shares held indirectly through Mountainview Investment Holdings LLC, which he wholly controls as a director.
LakeShore Biopharma Co., Ltd. director and Chief Executive Officer Wang Xu reported an initial holding of a stock option in a Form 3. The option gives the right to acquire 203,464 ordinary shares at an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, contingent on continued service with the company.
LakeShore Biopharma Co., Ltd. director Xue Linnan has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing establishes their status as a director and formally begins periodic ownership reporting, but does not itself reflect any buy or sell transaction.